EFFECTS OF ABATACEPT on the Progression to Rheumatoid Arthritis(PALABA Study)

Summary

The main objective of this trial is to test the hypothesis that abatacept can reduce the progression of rheumatoid arthritis in ACPA+ or RF+ patients with palindromic rheumatism compared with patients treated with hydroxychloroquine.

Timeline

Start

2019-06-03

Primary completion

2022-06-30

Completion

2024-09-30

Publications

• Sanmarti R, Perez-Garcia C, de-Toro FJ, Salvador G, Escudero-Contreras A, Cuervo A, Graell E, Reina D, Kanterewicz E, Corominas H, Urionaguena-Onaindia I, Lopez-Lasanta M, Olive A, Sala-Gomez M, Frade-Sosa B, Morla-Novell RM, Polino L, Meraz-Ostiz JA, Oreiro N, Blanco FJ, Perez-Nadales I, Ortega-Castro R, Busquets-Perez N, Gomez-Centeno AD, Camacho O, Rodriguez-Cros JR, Millan-Arciniegas AM, Garcia-Llorente JF, Borrell H, Prior-Espanol A, Castell-Quinones S, Cruceta A, Bonfill E, Domenech-Gomez G, Roca-Fabregas A, Rios J, Tobalina-Maestre L, Gomara MJ, Haro I. Abatacept versus hydroxychloroquine for prevention of rheumatoid arthritis in individuals with palindromic rheumatism: a randomized open-label trial. Nat Med. 2026 Jul;32(7):2610-2618. doi: 10.1038/s41591-026-04395-6. Epub 2026 May 14.

Drugs

Indications